A Phase 1B, Open Label, Dose-finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 10 Sep 2018 Status changed from suspended to recruiting.
- 26 Apr 2018 Status changed from recruiting to suspended as adding ancillary components, will reopen once amendment is IRB approved.
- 02 Mar 2018 Status changed from not yet recruiting to recruiting.